Please note that this is archived content and may no longer reflect current information or practices
In 2018 Canada became one of the first countries in the world to legalize the recreational use of cannabis. In late 2019 the country’s Parliament enacted additional legislation – known as Cannabis 2.0 – allowing for the sale of cannabis-infused beverages and edibles.
As a result of these developments, investors injected billions of dollars into the legal pot industry – but it hasn’t been plain sailing for them or for cannabis companies, which have had to contend with long delays in licensing and the slow formation of government-regulated retail dispensary networks.
One company that has successfully navigated the challenge is MediPharm Labs. Founded in 2015 in the town of Barrie, Ontario north of Toronto, it set out with a different vision and business model from other cannabis companies. While others opted for vertical integration, which required the establishment of costly plant cultivation networks, MediPharm chose to focus only on the highest-value part of the supply chain: extraction.
And while others were content to compete domestically for their share of the Canadian recreational market, MediPharm had global aspirations that included serving pharmaceutical companies and research institutions that were addressing medical cannabis users. In this article you will read about:
- MediaPharm’s new approach to pharmaceutical cannabis and to investor relations
- How the company is poised for global growth
- The importance of a good IR program in the cannabis sector.
Please complete the form below with the information requested. Once you have filled in the form, you will receive or be taken to the white paper.
We need this information so that we can make the white paper available to you, and so that we and MediPharm Labs can keep you updated via email and telephone of our products and services.
Neither IR Magazine nor MediPharm Labs will share this information with any third parties, and will only process it in accordance with our respective privacy policies, available here: IR Magazine privacy policy and MediPharm Labs privacy policy.
You may choose to unsubscribe at any time by clicking on the “unsubscribe” link in any email communication from IR Magazine or MediPharm Labs.
>>
